Concord Biotech Performance
- Today's Low
- ₹1,116
- Today's High
- ₹1,177
- 52 Week Low
- ₹987
- 52 Week High
- ₹2,150
- Open Price₹1,129
- Previous Close₹1,123
- Volume180,172
- 50 DMA₹1,130.93
- 100 DMA₹1,192.87
- 200 DMA₹1,325.80
Concord Biotech Chart
Investment Returns
- Over 1 Month + 11.41%
- Over 3 Month + 5.91%
- Over 6 Month -18.55%
- Over 1 Year -22.99%
Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!
Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 38.9
- PEG Ratio
- -9.2
- Market Cap Cr
- 12,165
- P/B Ratio
- 6.4
- Average True Range
- 47
- EPS
- 30.1
- Dividend Yield
- 0.9
- MACD Signal
- 14.68
- RSI
- 49.71
- MFI
- 42.83
Latest Stock News Updates
Biotechnology company Concord Biotech announced Q3FY26 results Revenue: Rs 278 crore against Rs 244 crore during Q3FY25, change 14%. EBITDA: Rs 99 crore against Rs 98 crore during Q3FY25, change 1%. EBITDA Margin: 35.6% for Q3FY26. PBT: Rs 86 crore against Rs 101 crore during Q3FY25, change -15%. PAT: Rs 64 crore against Rs 76 crore during Q3FY25, change -16%. PAT Margin: 22.9% for Q3FY26. Ankur Vaid, Joint Managing Director & Chief Executive Officer, Concord Biotech, said: Revenue for Q3FY26 grew by 14%, driven primarily by strong performance in the API segment. Following receipt of written confirmation from CDSCO, order execution has stabilized and visibility has improved. We are also witnessing positive on-ground momentum, supported by improved clarity on the US tariff environment and progress on the India–EU trade deal. We expect this to translate into higher order inflows, increased secondsource opportunities, and growing CDMO engagements. EBITDA margins for the quarter stood at 35.6%, impacted by expenses related to the commercialization of the new injectable facility commissioned in March 2025 and the setup costs of our US subsidiary Stellon Biotech Excluding these factors, EBITDA margins would have been ~40% for Q3 & 9MFY26. The API segment delivered robust growth of 24% during the quarter, driven by volume-led expansion and sustained market share gains. Looking ahead, we remain optimistic about the demand environment and increased product uptake, which we believe will help us sustain our historical growth trajectory. On the strategic front, we achieved two important milestones. We received WHO-GMP certification for our injectable facility, enabling entry into the domestic Indian market through own-brand launches and contract development opportunities. In addition, we established our US subsidiary, Stellon Biotech, to drive marketing, distribution, and commercialization of Concord Biotech’s products in the US, creating a direct commercial footprint and supporting long-term global market expansion. Result PDF
- Trendlyne
- 3 months 1 week ago
Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E
- Business Standard
- 4 months 2 weeks ago
Conference Call with Concord Biotech Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 6 months 1 week ago
Concord Biotech Financials
Concord Biotech Technicals
EMA & SMA
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹1,129.11
- 50 Day
- ₹1,130.93
- 100 Day
- ₹1,192.87
- 200 Day
- ₹1,325.80
Resistance and Support
- R3 1,165.23
- R2 1,151.57
- R1 1,137.43
- S1 1,109.63
- S2 1,095.97
- S3 1,081.83
Concord Biotech Corporate Actions - Bonus, Splits, Dividends
About Concord Biotech
Concord Biotech Ltd. is leading biotechnology company in India, specializing in development & manufacturing of fermentation based biopharmaceuticals. Established in 2000, company has grown to become significant player in global biotech industry, with strong focus on immunosuppressants, oncology, & nephrology products. Concord Biotech's state of the art manufacturing facilities are designed to meet international quality standards, enabling company to supply its products to over 70 countries worldwide. company's dedication to innovation, research, & development has made it trusted partner in global healthcare industry.
diversified clientele: 200 clients in more than 70 countries use company's API & formulation solutions. long-term supply agreements with these clients accounted for 14.06%, 12.45%, & 12.56% of their revenues in FY21, FY22, & FY23.
R&D: Concord maintains specialized R&D facilities for formulations & APIs in Dholka & Valthera. Both have Indian DSIR's approval. Their R&D units employed 148 people as of March 31, 2022, making up 11.99% of their total number of permanent employees.
Domestic Presence: They sell range of 27 products in India, including immunosuppressants, nephrology medications, & anti-infective medications used in critical care. In India, they are present in 20 states & 5 union territories.
View More- NSE Symbol
- CONCORDBIO
- BSE Symbol
- 543960
- Chairman & Managing Director
- Mr. Sudhir Vaid
- ISIN
- INE338H01029
Similar Stocks to Concord Biotech
Popular Stocks
Concord Biotech FAQs
Concord Biotech share price is ₹1,162 As on 22 May, 2026 | 14:33
The Market Cap of Concord Biotech is ₹12164.8 Cr As on 22 May, 2026 | 14:33
The P/E ratio of Concord Biotech is 38.9 As on 22 May, 2026 | 14:33
The PB ratio of Concord Biotech is 6.4 As on 22 May, 2026 | 14:33
Consider company's product pipeline & growth prospects in biotech industry before investing.
Key metrics include revenue from key therapeutic areas, R&D investment, & profit margins.
Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Concord Biotech share, you can then put order as you prefer.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.